Dariohealth Corp - DRIO STOCK NEWS

DarioHealth Corp. (Nasdaq: DRIO) announced its digital therapeutics solutions will be integrated into Vitality Group's new Gateway Flex offering. This partnership aims to provide employers with personalized healthcare solutions, enhancing employee engagement and cost-effectiveness. Dario's President, Rick Anderson, expressed confidence that this inclusion validates their digital therapeutic solutions. The partnership with Vitality Group, initiated in March 2020, aims to accelerate Dario's reach within the self-insured employer market, catering to the increasing demand for tailored health applications.

DarioHealth Corp. (Nasdaq: DRIO) has partnered with HMC HealthWorks to integrate its digital therapeutics solutions into HMC's care management programs. This collaboration enables HMC to offer DarioHealth's platform both independently and as part of its comprehensive health management services. DarioHealth aims to enhance chronic condition management for patients, validating its transition to a digital therapeutics provider. The partnership is expected to expand DarioHealth's distribution and build a client pipeline within HMC's extensive customer base.

DarioHealth Corp. (Nasdaq: DRIO) has appointed Eric Milledge as Chairman of its newly-formed Scientific Advisory Board (SAB). With over 34 years at Johnson & Johnson, Milledge brings extensive experience in pharmaceuticals and medical devices. His leadership roles included overseeing successful product launches and managing strategic hospital contracts. At DarioHealth, he will guide the SAB in enhancing digital therapeutics for chronic conditions, focusing on creating data supporting Dario's technology platform and expanding its offerings, like the integration of continuous glucose monitors.

DarioHealth Corp. (Nasdaq: DRIO) announced the acceptance of a poster for presentation at the virtual ADCES 2020 Annual Conference from August 13-16, 2020. The poster titled "Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension" highlights a study with 345 participants using Dario's digital therapeutics platform. Results show a 70% improvement in blood pressure and significant reductions in glucose levels among users diagnosed with diabetes. The findings position Dario's platform as a valuable tool for managing chronic diseases.

DarioHealth Corp. (Nasdaq: DRIO) will announce its second quarter financial results for the period ending June 30, 2020, on August 12, 2020. Following the release, a conference call will be held at 9:00 AM EDT, featuring key executives including CEO Erez Raphael and CFO Zvi Ben-David. Participants can join the call using provided dial-in numbers, and a replay will be available shortly after the call until August 26, 2020. DarioHealth specializes in digital therapeutics, enhancing the management of chronic conditions through innovative technology.

DarioHealth Corp. (Nasdaq: DRIO) has successfully completed a private placement transaction, raising approximately $28.6 million from accredited investors in the U.S. and Israel. This funding positions the company at its best financial state since its inception, aiming to transition from a direct-to-consumer model to a more profitable business-to-business-to-consumer strategy. Proceeds will enhance commercial infrastructure and secure contracts with health plans and employers. The transaction closed on July 31, 2020, with shares priced at $7.47 and $7.94.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic partnership with Williams Medical to launch its Remote Patient Monitoring (RPM) platform across the UK and Ireland. This initiative aims to assist healthcare professionals in managing chronic conditions, alleviating pressures from the COVID-19 pandemic. Dario's RPM solution enhances patient care while reducing healthcare provider workloads. The partnership leverages Williams Medical's extensive network of over 8,000 practices, enhancing Dario's growth strategy outside the U.S. and targeting chronic conditions like diabetes.

DarioHealth Corp. (Nasdaq: DRIO) announced the appointment of Dennis A. Matheis to its Board of Directors as of July 2, 2020. Matheis, president of Optima Health, brings nearly 30 years of healthcare experience. His expertise is expected to enhance Dario's transition to a business-to-business-to-consumer model, focusing on chronic disease management. DarioHealth is known for its digital therapeutic solutions, particularly its MyDario™ app, which is well-regarded in the market.